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BACKGROUND: Evidence from experimental animal and cell line studies supports a beneficial role for vitamin D in prostate cancer
(PCa). Although the results from human studies have been mainly null for overall PCa risk, there may be a benefit for survival. This
study assessed the associations of circulating 25-hydroxyvitamin D (25(OH)D) and common variations in key vitamin D–related genes
with fatal PCa. METHODS: In a large cohort consortium, 518 fatal cases and 2986 controls with 25(OH)D data were identified. Geno-
typing information for 91 single-nucleotide polymorphisms (SNPs) in 7 vitamin D–related genes (vitamin D receptor, group-specific
component, cytochrome P450 27A1 [CYP27A1], CYP27B1, CYP24A1, CYP2R1, and retinoid X receptor a) was available for 496 fatal
cases and 3577 controls. Unconditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs)
for the associations of 25(OH)D and SNPs with fatal PCa. The study also tested for 25(OH)D-SNP interactions among 264 fatal cases
and 1169 controls. RESULTS: No statistically significant relationship was observed between 25(OH)D and fatal PCa (OR for extreme
quartiles, 0.86; 95% CI, 0.65-1.14; P for trend5 .22) or the main effects of the SNPs and fatal PCa. There was evidence suggesting that
associations of several SNPs, including 5 related to circulating 25(OH)D, with fatal PCa were modified by 25(OH)D. Individually, these
associations did not remain significant after multiple testing; however, the P value for the set-based test for CYP2R1 was .002.
CONCLUSIONS: Statistically significant associations were not observed for either 25(OH)D or vitamin D–related SNPs with fatal PCa.
The effect modification of 25(OH)D associations by biologically plausible genetic variation may deserve further exploration. Cancer
2015;121:1949-56. VC 2015 American Cancer Society.
KEYWORDS: circulating 25-hydroxyvitamin D, fatal prostate cancer, gene-environment interaction, single-nucleotide polymorphisms,
vitamin D genes.
INTRODUCTION
In addition to its role in bone health, vitamin D regulates the expression of 3% to 5% of genes, many of which are related
to cancer.1 Evidence from experimental animal and cell line studies supports a beneficial role for vitamin D in the
prevention and treatment of prostate cancer (PCa),2,3 but results from human epidemiologic studies are conflicting.
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Epidemiologic studies focusing on circulating 25-
hydroxyvitamin D (25(OH)D) have not supported a pro-
tective association for higher 25(OH)D with overall PCa
risk.4-8 More recently, there has been growing interest in
whether vitamin D may specifically influence cancer sur-
vival and prognosis.9 This is particularly relevant for PCa
because indolent and fatal disease may be etiologically dif-
ferent.10 However, only a few studies have investigated
the relationship between circulating 25(OH)D and PCa-
specific mortality; some have found a protective associa-
tion,6,11,12 whereas others have not.7,13
At the same time, an increasing number of studies
have explored whether common genetic variants among
genes that play a role in vitamin Dmetabolism and signal-
ing are associated with PCa risk. Most studies have
focused on 5 specific single-nucleotide polymorphism
(SNPs) in the vitamin D receptor (VDR) gene, and results
have been inconsistent.14 More comprehensive studies
assessing common variations across VDR and several other
vitamin D pathway genes and PCa risk have yielded few
additional findings.15-18 Furthermore, only 2 studies have
assessed the relationship of common variations in these
vitamin D pathway genes with the endpoint of fatal PCa;
although both studies found suggestive associations, their
results were not consistent.6,19 A yet unexplored area is
whether associations between vitamin D–related SNPs
and fatal PCa may be modified by circulating levels of
25(OH)D. The identification of such interactions would
lend mechanistic and causal support to an association of
vitamin D with PCa.
Recently, the Health Professionals Follow-Up Study
(HPFS) reported that higher prediagnostic 25(OH)D lev-
els were associated with a statistically significant reduction
(57%) in the risk of fatal PCa (highest quartile vs lowest
quartile).6 Using a pathway-based approach, HPFS also
reported that common variations in 7 vitamin D–related
genes (cytochrome P450 27A1 [CYP27A1], CYP2R1,
CYP27B1, group-specific component [GC], CYP24A1,
retinoid X receptor a [RXRA], and VDR) were related to
fatal PCa (particularly VDR and CYP27A1).6 The genes
were chosen because of laboratory evidence showing that
they are directly involved in vitamin D metabolism and
signaling.
The objectives of the current study were to follow up
the findings fromHPFS within a large consortium of pro-
spective cohort studies. Specifically, we 1) assessed
whether men with low circulating 25(OH)D are at
increased risk for fatal PCa and 2) investigated the associa-
tion of common variations in vitamin D pathway genes
with fatal PCa. Furthermore, we also explored gene-
environment interactions between circulating 25(OH)D,
vitamin D pathway SNPs, and fatal PCa.
MATERIAL AND METHODS
Study Population
The Breast and Prostate Cancer Cohort Consortium is a
collaboration of well-established prospective cohort stud-
ies investigating genetic risk factors for breast cancer and
PCa, and it has been described in detail previously.20
Studies that participated in this analysis included the
Alpha-Tocopherol, Beta-Carotene Cancer Prevention
Study,7 the European Prospective Investigation into Can-
cer and Nutrition,5 HPFS,6 the Physicians’ Health
Study,21 and the Prostate, Lung, Colorectal, and Ovarian
Cancer Screening Trial.15 The respective local institu-
tional review boards approved each study. Each cohort
provided a nested series of PCa cases and controls; within
each cohort, controls without a previous diagnosis of PCa
were matched to cases by factors such as age and ethnicity
(depending on the cohort).20 In addition, covariate infor-
mation, including the body mass index (kg/m2), history
of diabetes (yes or no), smoking status (never, current, or
former), and age at blood draw and diagnosis, were avail-
able. We restricted the current study to men who self-
reported being of European descent.
Outcome Ascertainment
Men with incident PCa were identified through
population-based cancer registries or self-reports con-
firmed by medical records, including pathology reports.
Data on the disease stage and grade at the time of diagno-
sis were noted when they were available. The primary out-
come was fatal PCa risk. Cases were followed for overall
mortality and PCa-specific mortality with a combination
of death certificates, medical record review, and popula-
tion registries.
25(OH)D Assessment
Prediagnostic circulating 25(OH)D levels were assayed
separately in each study and were available for 518 fatal
PCa cases and 2986 controls. Details of the 25(OH)D
assessment specific to each cohort, including the type of
assay and quality control measures, have been previously
published5-7,15,21 (see also Supporting Table 1 [see online
supporting information]). Some studies conducted multi-
ple batches of assays at different time points (eg, HPFS
selected cases and controls in 4 separate batches, and each
batch was assayed at a different time point: blood draw to
January 1996, February 1996 to January 1998, February
1998 to January 2000, and February 2000 to January
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2004). To account for study, season of blood draw, and
laboratory variation due to multiple batches of assays con-
ducted at different time points within a study, we created
study, season, and batch quartile and median cut points
based on levels in the control subjects. Seasons were
defined as summer (June to August)/autumn (September
to November) and spring (March to May)/winter (De-
cember to February). We did not analyze absolute cut
points of 25(OH)D because of substantial variation
among the different assays.
Genotyping
A subset of the Breast and Prostate Cancer Cohort Con-
sortium cases with aggressive PCa (defined as a Gleason
score of 8 to 10 or stage C/D) and controls were included
in a genome-wide association study (GWAS) to identify
novel risk variants for aggressive PCa (496 fatal PCa cases
and 3577 controls).20 Genotyping was performed for the
majority of the subjects with the Illumina Human 610-
Quad array, but some subjects from the Prostate, Lung,
Colorectal, and Ovarian Cancer Screening Trial were gen-
otyped with other Illumina arrays (ie, HumanHap
317K1240K or 550K). Quality control measures have
been described in detail elsewhere.20 In brief, samples
were excluded if the genotyping call rate was <95% or
autosomal heterozygosity was <0.25 or>0.35. Additional
common variants and missing values were imputed with a
Markov chain–based haplotyper (MACH) and phase 2
CEU (Utah residents with ancestry from northern and
western Europe). HapMap data.22 We were able to extract
genotypes or a proxy (R2 0.8) for 88 of the 95 SNPs
included in the original study. Four of the SNPs, including
the VDR SNPs rs2228570 (Fok1), rs11168275, and
rs11574032 and the RXRA SNP rs34312136, were unavail-
able, and 3 SNPs (rs10875693 [VDR] and rs7853934
and rs41400444 [RXRA]) were partially tagged
(0.6<R2< 0.8). Among the men with GWAS data, there
were 264 fatal PCa cases and 1169 controls who also had
overlapping information on circulating 25(OH)D.
Statistical Methods
All statistical tests were 2-sided and were conducted with
SAS 9.3 (SAS Institute, Cary, NC) and R statistical pack-
ages (http://www.r-project.org/). We used logistic regres-
sion to calculate the odds ratios (ORs) and 95%
confidence intervals (CI) for the associations of circulating
25(OH)D and vitamin D pathway SNPS with the risk of
incident fatal PCa in comparison with controls. The pri-
mary models used data pooled across all 5 cohorts and
were adjusted for the age at diagnosis (cases) or selection
(controls) and cohort.
For 25(OH)D, we also created models adjusted for
the year of blood draw, time from blood draw to diagno-
sis, body mass index (kg/m2), diabetes history (yes or no),
and smoking (never, current, or former). The lowest quar-
tile of 25(OH)D was used as the reference category, and
tests for trends used an ordinal variable (1-4) correspond-
ing to the quartile in which the individual’s circulating
25(OH)D fell. We conducted a sensitivity analysis
excluding men who were diagnosed with PCa within the
first 2 years after the blood draw. For the SNP analyses,
we used an allele-dosage model. Finally, we conducted ex-
ploratory analyses to test for SNP-25(OH)D interactions
with respect to fatal PCa risk among the subset of men
with both circulating 25(OH)D and genetic data.We per-
formed a stratified analysis for the association of the SNPs
with fatal PCa in those men with high 25(OH)D versus
low 25(OH)D (dichotomized at the median). We tested
for a multiplicative interaction by adding a cross-product
term to the model (SNP325(OH)D) and assessed signifi-
cance with the Wald test. To improve the power of the
statistical test for interaction, we used a continuous mea-
sure of 25(OH)D that was standardized for the season,
cohort, and batch with the method described by Rosner
et al.23 Briefly, with this method, b coefficients from a lin-
ear regression model of 25(OH)D with batch, season, and
cohort indicators were averaged; for each specific cohort-
season-batch combination, the difference between the
corresponding beta coefficient from the model and the av-
erage coefficient was subtracted from the unadjusted
25(OH)D value to create a continuous measurement that
was standardized to the average cohort-season-batch
combination.
We implemented set-based tests across the entire
pathway of 7 genes and at the individual gene level for the
association with fatal PCa and for SNP-25(OH)D inter-
actions. A set-based test may have enhanced power
because it aggregates multiple signals within a set, lever-
ages the correlation between SNPs, and reduces the multi-
ple testing burden. The mathematical details of the
logistic regression kernel machine models and gene-
environment set-based association test (GESAT) are
described elsewhere.24-27 In brief, the kernel machine
model treats each of the included SNPs as a random effect;
desired covariates (eg, age and study) are entered as fixed
effects. The joint effect of the entire SNP set are consid-
ered, and the degrees of freedom are calculated with
respect to the correlation between the SNPs in the set; this
improves the power of the hypothesis test. The null hy-
pothesis that the variance of the SNP random effects is
zero (ie, the SNPs individually or jointly are not associated
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with disease) can be tested with a score test. Similarly, the
GESAT27 considers the coefficients of the gene-
environment interaction terms as random effects and
develops a variance component score test within the
induced generalized linear mixed model framework.
We report nominal P values, but we also calculated
the effective number of independent tests for the individual
SNP associations.28 After we accounted for linkage disequi-
librium, the 91 SNPs corresponded to 77 independent tests;
therefore, a P value significance threshold of .0006 controls
the experiment-wide type I error rate at the .05 level.
RESULTS
Supporting Table 2 (see online supporting information)
describes the characteristics of the fatal PCa cases and con-
trols for those with 1) circulating 25(OH)D data, 2) geno-
type data, and 3) both circulating 25(OH)D and GWAS
information. Those participating in the GWAS were
more heavily weighted to a higher stage and grade because
of the selection criteria described previously.
25(OH)D and Fatal PCa
Among the men with prediagnostic circulating 25(OH)D
data, 518 died from PCa over a median follow-up time of
8.1 years after their diagnosis. The median levels of
25(OH)D in the first and fourth quartiles were 14.4 ng/
mL (35.9 nmol/L) and 33.0 ng/mL (82.4 nmol/L),
respectively. Table 1 shows the ORs and 95% CIs by
quartiles of circulating 25(OH)D for the risk of fatal PCa
adjusted for the age at blood draw, time from blood draw
to diagnosis and cohort, and body mass index. There was
no significant association of 25(OH)D and the risk of
fatal PCa across the 5 cohorts combined (OR for highest
quartile vs lowest quartile, 0.86; 95% CI, 0.65-1.14; P for
trend5 .22). Three of the 5 cohorts showed an inverse
trend, but only 1 cohort (HPFS) was statistically signifi-
cant (Supporting Table 3 [see online supporting informa-
tion]). When we excluded HPFS, the pooled results
remained nonsignificant (OR for highest quartile vs low-
est quartile, 0.96; 95% CI, 0.70-1.31; P for trend5 .73;
data not shown). There was no evidence for heterogeneity
between studies when we looked at the estimates for the
highest quartile versus the lowest quartile with Cochran’s
Q test. Additional adjustments for diabetes status and
smoking did not change the results.
Common Genetic Variation in Vitamin D
Pathway and Fatal PCa
Among the men with available genotype information,
496 died of PCa. Figure 1 shows the P value for the per-
TABLE 1. ORs and CIs for Quartiles of Circulating 25(OH)D and Fatal Prostate Cancer Pooled Across 5
Cohorts
25(OH)D Quartile
P for
TrendFirst Second Third Fourth
Median 25(OH)D level, ng/mLa 14.4 20.1 24.8 33.0
Cases/controls 141/740 131/751 120/757 126/738
OR (95% CI)b 1.00 (reference) 0.87 (0.66-1.15) 0.79 (0.60-1.05) 0.86 (0.65-1.14) .22
Results excluding cases diagnosed
within 2 years of blood draw
Cases/controls 113/740 112/751 103/757 110/738
OR (95% CI)b 1.00 (reference) 0.92 (0.68-1.23) 0.85 (0.63-1.16) 0.94 (0.69-1.27) .59
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; OR, odds ratio.
25(OH)D quartiles are batch-, season- (summer/fall vs winter/spring), and cohort-specific.
a Among controls, the median values for 25(OH)D were 35.9, 50.2, 61.9, and 82.4 nmol/L in the first, second, third, and fourth quartiles, respectively.
b Adjusted for the age at blood draw, the time from blood draw to diagnosis, cohort, and body mass index.
Figure 1. Manhattan plot showing P values for the association
of each individual vitamin D single-nucleotide polymorphism
and fatal prostate cancer risk. Each single-nucleotide poly-
morphism is color-coded by gene and is represented as a
circle on the plot. CYP indicates cytochrome P450; GC,
group-specific component; RXRA, retinoid X receptor a; VDR,
vitamin D receptor.
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allele associations of each SNP and fatal PCa, and Sup-
porting Table 4 (see online supporting information) pro-
vides the OR and 95% CI for each SNP. None of the
SNPs were significantly associated with fatal PCa, and the
global P value across the pathway from the kernel machine
test was not significant (P5 .44).
SNP-25(OH)D Interactions and Fatal PCa
In the subset of men who had both circulating 25(OH)D
and genotype data, there were 264 PCa deaths. Table 2
details the SNPs that either were nominally significant in
strata of high vitamin D (n5 6) or low vitamin D
(n5 11) or had a P for interaction value< .05 (n5 9);
none of the SNPs remained statistically significant after
we considered multiple testing, so these associations may
be due to chance. However, the results of the GESAT
across the entire pathway was P5 .06, and at the gene-
level, CYP2R1 was statistically significant (P5 .002).
Supporting Table 5 (see online supporting information)
includes the results for all of the SNPs and GESATs. We
also assessed whether the vitamin D pathway SNPs were
associated with circulating 25(OH)D levels. Our results
replicated SNPs in the genes GC and CYP2R1 known to
be related to circulating 25(OH)D from a previous
GWAS15 (Supporting Table 6 [see online supporting in-
formation]). Five of these SNPs (GC, rs1155563;
CYP2R1, rs2060793, rs12794714, rs1562902, and
rs11023374) were among the SNPs whose association
with fatal PCa differed with the circulating 25(OH)D
level (Table 2).
DISCUSSION
In our large cohort consortium, we did not find evidence
to support associations of circulating 25(OH)D or com-
mon variations in key vitamin D pathway genes with the
risk of fatal PCa. In our exploratory analysis for SNP-
25(OH)D interactions, several nominally significant asso-
ciations between vitamin D pathway SNPs and fatal PCa
were observed in the stratified analysis at either high or
low circulating 25(OH)D levels, and a significant gene-
level association was observed for CYP2R1.
The pooled association across all 5 cohorts between
higher circulating 25(OH)D and the risk of fatal PCa was
in the protective direction, but it was not statistically sig-
nificant. Three of the 5 cohorts showed an inverse trend,
but only HPFS (as published previously6) was statistically
significant. Other studies have published findings on cir-
culating 25(OH)D and fatal PCa.7,12,13 The Alpha-
TABLE 2. Associations of Nominally Significant Vitamin D Pathway SNPs and Lethal Prostate
Cancer Stratified by 25(OH)D (High Vs Low)
Gene:SNP
(Major/Minor Allele)
OR (95% CI) for
Low 25(OH)D Strata P
OR (95% CI)
for High 25(OH)D
Strata P
P for
Interactiona
VDR:rs2239186(A,G) 1.26 (0.88-1.78) .20 1.44 (1.01-2.05) .04 .44
VDR:rs2189480(G,T) 1.44 (1.05-1.97) .02 1.12 (0.83-1.50) .47 .60
VDR:rs2283342(A,G) 1.07 (0.72-1.57) .75 1.59 (1.09-2.32) .02 .15
VDR:rs12721364(G,A) 1.34 (0.89-2.02) .16 0.67 (0.44-1.02) .06 .05
VDR:rs10875693(T,A) 0.66 (0.46-0.96) .03 1.16 (0.82-1.64) .42 .23
VDR:rs4760648(C,T) 0.85 (0.63-1.14) .27 1.23 (0.90-1.69) .19 .03
GC:rs1155563(T,C) 0.96 (0.69-1.33) .81 1.54 (1.10-2.14) .01 .12
GC:rs1491716(G,A) 0.50 (0.25-0.98) .04 1.25 (0.68-2.30) .48 .70
GC:rs6817912(C,T) 1.93 (1.00-3.70) .05 0.93 (0.48-1.81) .83 .72
GC:rs12640179(C,G) 1.81 (0.99-3.31) .05 0.72 (0.36-1.48) .37 .03
CYP27A1:rs647952(A,G) 0.20 (0.05-0.74) .02 1.28 (0.48-3.41) .63 .51
CYP2R1:rs2060793(G,A) 1.34 (1.00-1.79) .05 1.13 (0.84-1.52) .42 .03
CYP2R1:rs12794714(G,A) 0.69 (0.51-0.93) .01 0.86 (0.63-1.16) .32 .04
CYP2R1:rs1562902(T,C) 1.41 (1.04-1.90) .03 1.05 (0.79-1.42) .72 .004
CYP2R1:rs10832312(T,C) 1.65 (1.02-2.65) .04 0.88 (0.52-1.49) .64 .04
CYP2R1:rs11023374(T,C) 0.75 (0.53-1.07) .11 0.97 (0.68-1.38) .85 .01
CYP24A1:rs2585413(G,A) 0.93 (0.67-1.29) .67 0.71 (0.51-0.98) .04 .48
CYP24A1:rs2585415(G,A) 0.99 (0.72-1.35) .93 0.70 (0.51-0.96) .03 .21
CYP24A1:rs927650(C,T) 0.99 (0.73-1.33) .94 1.50 (1.11-2.04) .009 .19
CYP24A1:rs3787555(C,A) 1.40 (1.00-1.96) .05 0.81 (0.57-1.16) .25 .78
RXRA:rs1536475(G,A) 1.09 (0.73-1.61) .69 0.79 (0.51-1.20) .27 .03
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; CYP, cytochrome P450; GC, group-specific component; OR, odds ratio; RXRA, retinoid
X receptor a; SNP, single-nucleotide polymorphism; VDR, vitamin D receptor.
OR per minor allele for fatal prostate cancer (adjusted for the age at diagnosis).
aWald P values for the SNP coded (0,1,2)325(OH)D (continuous). 25(OH)D was standardized by the cohort, season, and laboratory assay batch.
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Tocopherol, Beta-Carotene Cancer Prevention Study
(294 fatal PCa cases) did not find a statistically significant
association between prospectively collected circulating
25(OH)D and fatal PCa.7 Two studies assessed the associ-
ation of progression to PCa-specific mortality and
25(OH)D in postdiagnostic blood. A population-based
study performed in 1476 men with PCa in the metropoli-
tan Seattle–Puget Sound area found no significant associ-
ation for progression to PCa-specific mortality,13 whereas
a different study based on 160 Norwegian men observed a
statistically significant 67% decreased risk of progression
with medium to high 25(OH)D levels versus low levels
(<50 nmol/L), especially in men receiving hormone ther-
apy.12 A study combining data fromHPFS and the Physi-
cians’ Health Study also found a protective association
between prediagnostic circulating 25(OH)D and PCa
mortality among cases, but the association was mostly
driven by HPFS.11 A few studies have generated concern
that there may be an increased risk of aggressive PCa with
higher circulating 25(OH)D15,29; our study does not sup-
port an increased risk of fatal PCa with higher levels of cir-
culating 25(OH)D.
Varying results by cohort could be due to differences
in screening practices, the severity of disease at diagnosis,
the prevalence of factors that could modify the associa-
tion, or chance. The Prostate, Lung, Colorectal, and
Ovarian Cancer Screening Trial and HPFS both involved
highly screened populations and showed the strongest
protective associations for vitamin D with fatal PCa. It is
difficult to explain this observation, but one potential hy-
pothesis is that vitamin D may be more effective in pre-
venting progression in prostate-specific antigen–screened
populations in which disease is treated early; cancers
detected at a later point in the natural history of the dis-
ease could be more likely to be resistant to this vitamin D
effect. There were no major differences in the range of
vitamin D levels in each cohort; in particular, the median
levels in the first and fourth quartiles in the controls were
comparable among the cohorts (Supporting Table 3 [see
online supporting information]). Overall, the difference
between the medians of the first and fourth quartiles of
25(OH)D in the controls was 18.6 ng/mL (46.5 nmol/L),
with more than a quarter of the men classified as at risk
for having inadequate vitamin D levels (<20 ng/mL or
<50 nmol/L; Table 2). Although a single measurement of
circulating 25(OH)D has been shown to have reasonable
validity over time,30 multiple measurements would more
accurately reflect long-term exposure. In addition, the
25(OH)D assays differed across cohorts and were not cali-
brated to a common assay, nor they were standardized to
an accepted gold standard; this prevented the use of abso-
lute cut points for comparisons.
We did not observe evidence for confounding by
body mass index, diabetes, or smoking, but we did not
have information on other potential confounders such as
physical activity. For example, if higher levels of physical
activity are associated with higher circulating 25(OH)D
levels6 and a lower risk for PCa mortality, the observed
results could be biased away from the null.
We did not observe any statistically significant main
effects of common variations in key vitamin D pathway–
related genes on the risk for fatal PCa. We did not repli-
cate the findings in the prior HPFS study6 or the findings
from a case-only study that assessed 48 tag SNPs in VDR,
CYP27B1, and CYP24A1 and progression to PCa
mortality.19
To our knowledge, this is the first study to assess
interactions between a comprehensive set of SNPs in key
genes related to vitamin D signaling and metabolism and
levels of circulating 25(OH)D with respect to fatal PCa.
An overall GESAT pathway P value of .06 and suggestive
effect modification by circulating 25(OH)D on the asso-
ciation of a number of SNPs and fatal PCa were observed.
Several of these SNPs were located in GC (the vitamin D–
binding protein) and CYP2R1 (a 25-hydroxylase), genes
that have been observed to influence circulating
25(OH)D levels.31 The strongest evidence for effect mod-
ification was in the CYP2R1 gene; 5 SNPs had nominally
significant P values for interaction, and the gene-level
GESAT was statistically significant (P5 .002). Interest-
ingly, 4 of these 5 CYP2R1 SNPS were associated with
levels of circulating 25(OH)D in our study. On average,
men who carried an allele that was associated with higher
circulating 25(OH)D levels in the general population but
who still had low circulating 25(OH)D levels were at
higher risk for fatal PCa. The other SNPs were mainly
located in CYP24A1, an enzyme critical for the catabolism
of vitamin D, and VDR, the key nuclear receptor that
mediates the genomic effects of vitamin D. Overexpres-
sion of CYP24A1 has been shown to correlate with worse
outcomes in several solid tumors, including prostate
tumors.32 Conversely, higher VDR expression has been
associated with better PCa survival.33 Because of the
strong biological plausibility of the idea that circulating
25(OH)D may affect the association of these SNPs with
fatal PCa, future study is warranted.
A few studies have assessed circulating 25(OH)D-
SNP interactions for overall PCa incidence. Most of these
studies were small candidate gene studies that focused
mainly on VDR polymorphisms, including Bsm1
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(rs1544410),15,34,35 Cdx2 (rs11568820),15,35 and Fok1
(rs2228570/rs10735810),15,21,35-37 and the results have
been inconclusive. Our study was unable to assess Fok1,
and we did not observe any gene-environment interac-
tions with Cdx2 or Bsm1. Recently, a study of 1514 par-
ticipants found that a variant in VDR (rs7968585)
modified the association of 25(OH)D and a composite
clinical outcome (incident hip fracture, myocardial infarc-
tion, cancer incidence, and total mortality). This finding
was further replicated through a meta-analysis of 3 inde-
pendent cohorts.38 Although not statistically significant,
our data were consistent with this finding. rs7967152
(r25 0.87 with rs7968585) showed a stronger association
with fatal PCa in men with low 25(OH)D (OR for low
25(OH)D, 1.30; 95% CI, 0.97-1.74; P5 .08) versus
those with high 25(OH)D (OR for high 25(OH)D, 0.89;
95% CI, 0.66-1.20; P5 .46; Supporting Table 6 [see
online supporting information]).
The relationship between circulating 25(OH)D and
the prostate environment is complex and could be medi-
ated by the expression of several vitamin D–related genes.
It is possible that circulating levels of 25(OH)D do not
adequately reflect the bioavailability in the prostate tissue
because CYP27B1 is expressed in the prostate and can syn-
thesize 1,25(OH)2D from 25(OH)D within the prostate.
Nonetheless, a clinical trial of vitamin D supplementation
indicated that levels of vitamin D metabolites (25(OH)D
and 1,25(OH)2D) in prostate tissue correlated positively
with serum circulating levels.39 The influence of 25(OH)D
in the prostate environment may be further mediated by
the expression of VDR or CYP24A1 in prostate tissue.
Higher expression of VDR in prostate tumor tissue has
been associated with a decreased risk of PCa progression,33
and increased expression of CYP24A1 has been observed to
be associated with advanced-stage PCa and resistance to
vitamin D–based therapies.32 Studies integrating circulat-
ing 25(OH)D with tumor molecular profiling could shed
light on the inconsistent results to date.
A major strength of this study was the combination
of several large cohort studies with prospective blood col-
lection and relatively long-term and complete follow-up;
this allowed the assessment of fatal PCa, an endpoint that
has been traditionally difficult to study epidemiologically
with substantial numbers of outcomes because of the long
natural history of the disease. With a median follow-up of
8.1 years, we were able to capture 518 fatal PCa cases.
Even so, longer follow-up would allow greater accrual of
deaths further in the natural history of the disease. Finally,
after the subsetting of the men who had both levels of cir-
culating 25(OH)D and genotyping data, our sample size
was reduced, and this limited our power to detect
interactions.
In conclusion, we did not find strong evidence to
support the hypothesis that circulating 25(OH)D or com-
mon variation in key vitamin D pathway genes is related
to a decreased risk of fatal PCa. We observed suggestive
modification of the association between some of the SNPs
and fatal PCa by circulating 25(OH)D levels, especially in
CYP2R1. These latter findings could be further assessed in
other cohort studies or in clinical trials of vitamin D sup-
plementation or vitamin D agonists.
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